BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang J, Zhou L, Zhao S, Dicker DT, El-Deiry WS. The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia. Cell Cycle 2017;16:1193-200. [PMID: 28486050 DOI: 10.1080/15384101.2017.1320005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Warfel NA. Targeting CDK4/6 to oppose hypoxia-mediated therapeutic resistance. Cell Cycle 2017;16:1241-2. [PMID: 28594259 DOI: 10.1080/15384101.2017.1337975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Sun W, Nie W, Wang Z, Zhang H, Li Y, Fang X. Lnc HAGLR Promotes Colon Cancer Progression Through Sponging miR-185-5p and Activating CDK4 and CDK6 in vitro and in vivo. Onco Targets Ther 2020;13:5913-25. [PMID: 32606801 DOI: 10.2147/OTT.S246092] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
3 Delou JM, Hajdu KL, Borges HL. Could combinations of new and old drugs enhance tumor cell death? Future Oncol 2018;14:2319-22. [PMID: 30139272 DOI: 10.2217/fon-2018-0339] [Reference Citation Analysis]
4 Bonelli M, Terenziani R, Zoppi S, Fumarola C, La Monica S, Cretella D, Alfieri R, Cavazzoni A, Digiacomo G, Galetti M, Petronini PG. Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells. Int J Mol Sci 2020;21:E5165. [PMID: 32708306 DOI: 10.3390/ijms21145165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Bi H, Shang J, Zou X, Xu J, Han Y. Palbociclib induces cell senescence and apoptosis of gastric cancer cells by inhibiting the Notch pathway. Oncol Lett 2021;22:603. [PMID: 34188705 DOI: 10.3892/ol.2021.12864] [Reference Citation Analysis]
6 Roberts PJ, Kumarasamy V, Witkiewicz AK, Knudsen ES. Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows. Mol Cancer Ther 2020;19:1575-88. [PMID: 32546660 DOI: 10.1158/1535-7163.MCT-18-1161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
7 DeLeon TT, Almquist DR, Kipp BR, Langlais BT, Mangold A, Winters JL, Kosiorek HE, Joseph RW, Dronca RS, Block MS, McWilliams RR, Kottschade LA, Rumilla KM, Voss JS, Seetharam M, Sekulic A, Markovic SN, Bryce AH. Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. PLoS One 2020;15:e0230306. [PMID: 32196516 DOI: 10.1371/journal.pone.0230306] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Zhang M, Dai W, Li Z, Tang L, Chen J, Chen C. HSPA4 Knockdown Retarded Progression and Development of Colorectal Cancer. Cancer Manag Res 2021;13:4679-90. [PMID: 34163243 DOI: 10.2147/CMAR.S310729] [Reference Citation Analysis]
9 Yu L, Ye F, Li YY, Zhan YZ, Liu Y, Yan HM, Fang Y, Xie YW, Zhang FJ, Chen LH, Ding Y, Chen KL. Histone methyltransferase SETDB1 promotes colorectal cancer proliferation through the STAT1-CCND1/CDK6 axis. Carcinogenesis 2020;41:678-88. [PMID: 31306481 DOI: 10.1093/carcin/bgz131] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
10 Kang YH, Lee JS, Lee NH, Kim SH, Seo CS, Son CG. Coptidis Rhizoma Extract Reverses 5-Fluorouracil Resistance in HCT116 Human Colorectal Cancer Cells via Modulation of Thymidylate Synthase. Molecules 2021;26:1856. [PMID: 33806077 DOI: 10.3390/molecules26071856] [Reference Citation Analysis]
11 Jin Q, Liu G, Bao L, Ma Y, Qi H, Yun Z, Dai Y, Zhang S. High Spy1 expression predicts poor prognosis in colorectal cancer. Cancer Manag Res 2018;10:2757-65. [PMID: 30147372 DOI: 10.2147/CMAR.S169329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol 2020;17:395-417. [PMID: 32203277 DOI: 10.1038/s41571-020-0341-y] [Cited by in Crossref: 147] [Cited by in F6Publishing: 164] [Article Influence: 73.5] [Reference Citation Analysis]
13 Xu Z, Qu H, Ren Y, Gong Z, Ri HJ, Chen X. An Update on the Potential Roles of E2F Family Members in Colorectal Cancer. Cancer Manag Res 2021;13:5509-21. [PMID: 34276228 DOI: 10.2147/CMAR.S320193] [Reference Citation Analysis]
14 Rencuzogulları O, Yerlikaya PO, Gürkan AÇ, Arısan ED, Telci D. Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells. J Cell Biochem 2020;121:508-23. [PMID: 31264276 DOI: 10.1002/jcb.29249] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
15 Somarelli JA, Roghani RS, Moghaddam AS, Thomas BC, Rupprecht G, Ware KE, Altunel E, Mantyh JB, Kim SY, McCall SJ, Shen X, Mantyh CR, Hsu DS. A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. Mol Cancer Ther 2020;19:2516-27. [PMID: 33158998 DOI: 10.1158/1535-7163.MCT-20-0454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Cretella D, Ravelli A, Fumarola C, La Monica S, Digiacomo G, Cavazzoni A, Alfieri R, Biondi A, Generali D, Bonelli M, Petronini PG. The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. J Exp Clin Cancer Res 2018;37:72. [PMID: 29587820 DOI: 10.1186/s13046-018-0741-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
17 Bjornsti MA, Kaufmann SH. Topoisomerases and cancer chemotherapy: recent advances and unanswered questions. F1000Res. 2019;8. [PMID: 31602296 DOI: 10.12688/f1000research.20201.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
18 Huang CY, Hsieh FS, Wang CY, Chen LJ, Chang SS, Tsai MH, Hung MH, Kuo CW, Shih CT, Chao TI, Chen KF. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response. Eur J Cancer 2018;102:10-22. [PMID: 30103095 DOI: 10.1016/j.ejca.2018.07.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
19 Wright P, Kelsall J, Healing G, Sanderson J. Differential expression of cyclin-dependent kinases in the adult human retina in relation to CDK inhibitor retinotoxicity. Arch Toxicol 2019;93:659-71. [PMID: 30617560 DOI: 10.1007/s00204-018-2376-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
20 Zhang J, Pei Y, Yang W, Yang W, Chen B, Zhao X, Long S. Cytoglobin ameliorates the stemness of hepatocellular carcinoma via coupling oxidative-nitrosative stress signals. Mol Carcinog 2019;58:334-43. [PMID: 30365183 DOI: 10.1002/mc.22931] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
21 Richter A, Schoenwaelder N, Sender S, Junghanss C, Maletzki C. Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies-Current Understanding, (Pre-)Clinical Application and Promising Approaches. Cancers (Basel) 2021;13:2497. [PMID: 34065376 DOI: 10.3390/cancers13102497] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 DeLeon TT, Ahn DH, Bogenberger JM, Anastasiadis PZ, Arora M, Ramanathan RK, Aqel BA, Vasmatzis G, Truty MJ, Oklu R, Bekaii-Saab TS, Borad MJ. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. Future Oncol 2018;14:553-66. [PMID: 29460642 DOI: 10.2217/fon-2017-0451] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]